Antibiotic

Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority

Retrieved on: 
Tuesday, May 18, 2021
Health sciences, Drug discovery, Pharmaceutical industry, Medical specialties, Antibiotic, California Air Resources Board, Vaccine, Preclinical development, Health care, Draft:CARB-X

Simultaneously, Summit has received an award from CARB-X to progress this candidate through preclinical development and Phase 1a clinical trials.

Key Points: 
  • Simultaneously, Summit has received an award from CARB-X to progress this candidate through preclinical development and Phase 1a clinical trials.
  • \xe2\x80\x9cSMT-738 has the potential to save the lives of patients with as yet untreatable infections through a novel drug class with a low propensity for resistance development.
  • CARB-X is investing up to US$480 million from 2016-2022 to support innovative antibiotics and other therapeutics, vaccines and rapid diagnostics.
  • Commercialization of ridinilazole for the treatment and the reduction of recurrence of CDI is subject to regulatory approvals.

Polyphor to Present at the UBS Global Healthcare Virtual Conference

Retrieved on: 
Tuesday, May 18, 2021
Bacteriology, Staining, Clinical medicine, Medicine, Eribulin, Macrocycles, Drugs, Antibiotic, Gram-negative bacteria

Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications.

Key Points: 
  • Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications.
  • In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA).
  • OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria.
  • Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN).

Spero Therapeutics to Participate at the Berenberg Conference USA

Retrieved on: 
Thursday, May 13, 2021
Health sciences, Articles, Health, Prodrugs, Tebipenem, Carbapenem, Multiple drug resistance, Antimicrobial resistance, Antibiotic

b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the Berenberg Conference USA, taking place virtually from May 18 \xe2\x80\x93 20, 2021.

Key Points: 
  • b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the Berenberg Conference USA, taking place virtually from May 18 \xe2\x80\x93 20, 2021.
  • Details for the fireside chat are as follows:\nA webcast of the fireside chat may also be accessed through Spero Therapeutics\xe2\x80\x99 website ( www.sperotherapeutics.com ) on the \xe2\x80\x9cEvents and Presentations\xe2\x80\x9d page under the \xe2\x80\x9cInvestors and Media\xe2\x80\x9d tab.
  • A replay of the fireside chat will be archived on the website for 90 days following the conclusion of the event.\nSpero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.\nSpero\xe2\x80\x99s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).
  • In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.\nSpero is also developing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.\nSpero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.\n'

Global Antimicrobial Resistance Diagnostic Markets, Strategies and Trends by Pathogen and Technology 2021-2025, with 30+ Company Profiles - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 12, 2021
Other Science, Science, Health sciences, Articles, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Life sciences, Antimicrobial resistance, Antibiotic, Antimicrobial, Infection

b'The "Antimicrobial Resistance Diagnostic Markets, Strategies and Trends by Pathogen and Technology, with Executive Guides and Customization - 2021 to 2025" report has been added to ResearchAndMarkets.com\'s offering.\nDiagnostics are leading the charge in reducing the threat posed by antimicrobial resistance.

Key Points: 
  • b'The "Antimicrobial Resistance Diagnostic Markets, Strategies and Trends by Pathogen and Technology, with Executive Guides and Customization - 2021 to 2025" report has been added to ResearchAndMarkets.com\'s offering.\nDiagnostics are leading the charge in reducing the threat posed by antimicrobial resistance.
  • Will these technologies solve the problem before new antibiotics come along?
  • New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market.\nThis report provides a plain language understanding of the different ways pathogens, and infections can be diagnosed.
  • The report has identified the 6 Key Large Pathogen Opportunities in this space and developed market forecasts.

Adaptive Phage Therapeutics Announces $40.75 Million Series B Financing

Retrieved on: 
Tuesday, May 11, 2021
Professional services, Health, Infectious diseases, Finance, Clinical trials, Pharmaceutical, Biotechnology, Health sciences, Life sciences, Articles, Bacteriophage, Biology, Antimicrobial resistance, Drug resistance, Multiple drug resistance, Antibiotic, Pathogen, Therapy

b'Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company.

Key Points: 
  • b'Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company.
  • Also joining the Series B round are existing investor Mayo Clinic and an additional undisclosed institutional investor.
  • Proceeds of this financing will be used to accelerate clinical development of PhageBank\xe2\x84\xa2 phage therapies, as well as for general corporate purposes.\nAPT\xe2\x80\x99s PhageBank\xe2\x84\xa2 technology is a growing collection of hundreds of bacteriophage, collectively providing broad spectrum coverage against six of the highest priority multi-drug resistant bacterial pathogens.
  • Together, we believe we can bring PhageBank\xe2\x84\xa2 therapy into the mainstream, and work to solve one of the key challenges facing modern medicine, the growing problem of antibiotic-resistant bacteria.\xe2\x80\x9d\nAdaptive Phage Therapeutics is a clinical-stage company advancing therapies to treat multi-drug resistant infections.

Iterum Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on May 14, 2021

Retrieved on: 
Friday, May 7, 2021
XC2, Penem, Antibiotic, Conference call

Management will host a conference call at\xc2\xa08:30 a.m. ET\xc2\xa0that day to discuss the Company\xe2\x80\x99s financial results and provide an update on its business.\nTo register for the conference call please use this link: https://www.incommglobalevents.com/registration/client/7304/iterum-thera... .

Key Points: 
  • Management will host a conference call at\xc2\xa08:30 a.m. ET\xc2\xa0that day to discuss the Company\xe2\x80\x99s financial results and provide an update on its business.\nTo register for the conference call please use this link: https://www.incommglobalevents.com/registration/client/7304/iterum-thera... .
  • \xc2\xa0\xc2\xa0 After registering, a confirmation email will be sent, including dial-in details and a unique code for entry.
  • Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation.
  • Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

SIGA Reports Financial Results for Three Months Ended March 31, 2021

Retrieved on: 
Thursday, May 6, 2021
Medical specialties, Chemical compounds, Infectious diseases, Biological warfare, Biodefense, Bioethics, Vaccine, Tecovirimat, Smallpox, Antibiotic, Biomedical Advanced Research and Development Authority

The FDA review process will typically take 10 months for this type of submission.\nIn March 2021, the Company announced a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to novel antibacterial drugs.

Key Points: 
  • The FDA review process will typically take 10 months for this type of submission.\nIn March 2021, the Company announced a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to novel antibacterial drugs.
  • Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness.
  • The oral formulation of TPOXX\xc2\xae was approved by the FDA for the treatment of smallpox in 2018.
  • For more information about SIGA, please visit www.siga.com .\nSmallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years.

Avivagen Continues Market Growth with New Customer Win in Western Mexico

Retrieved on: 
Thursday, May 6, 2021
Agriculture, Natural Resources, Health, Fitness & Nutrition, Veterinary, Meat industry, Antibiotic, Livestock, Forward-looking statement, Articles, OxC-beta™ Technology and OxC-beta™ Livestock, Avivagen, OXC-BETA™ TECHNOLOGY AND OXC-BETA™ LIVESTOCK, AVIVAGEN

Through support of immune function the technology provides a non-antibiotic means of promoting health and growth.

Key Points: 
  • Through support of immune function the technology provides a non-antibiotic means of promoting health and growth.
  • OxC-beta\xe2\x84\xa2 Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds.
  • Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates.
  • Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen\xe2\x80\x99s most recent management\xe2\x80\x99s discussion and analysis of financial condition available at www.SEDAR.com .

HeiQ launches high-tech mask featuring ground-breaking copper technology shown to deactivate the COVID-19 virus in five minutes

Retrieved on: 
Wednesday, May 5, 2021
Health, Medicine, Biocides, Antiviral drug, Surgical mask, Antifungal, Copper, Virus, Antibiotic, Bacteria

HeiQ MetalliX is a patent-pending technology, created by HeiQ\'s innovation partner,Australian materials technology company, Xefco.

Key Points: 
  • HeiQ MetalliX is a patent-pending technology, created by HeiQ\'s innovation partner,Australian materials technology company, Xefco.
  • The antiviral, antibacterial and antifungal properties of copper have been known for centuries and have been demonstrated by many laboratory studies.
  • HeiQ MetalliX treated materials release copper ions which deactivate viruses and bacteria.
  • Further, it gives an edgy look, making it an improved alternative to surgical masks in many ways," says Carlo Centonze, co-founder and CEO of HeiQ Group.\n'

HeiQ launches high-tech mask featuring ground-breaking copper technology shown to deactivate the COVID-19 virus in five minutes

Retrieved on: 
Wednesday, May 5, 2021
Health, Medicine, Biocides, Antiviral drug, Surgical mask, Antifungal, Copper, Virus, Antibiotic, Bacteria

HeiQ MetalliX is a patent-pending technology, created by HeiQ\'s innovation partner,Australian materials technology company, Xefco.

Key Points: 
  • HeiQ MetalliX is a patent-pending technology, created by HeiQ\'s innovation partner,Australian materials technology company, Xefco.
  • The antiviral, antibacterial and antifungal properties of copper have been known for centuries and have been demonstrated by many laboratory studies.
  • HeiQ MetalliX treated materials release copper ions which deactivate viruses and bacteria.
  • Further, it gives an edgy look, making it an improved alternative to surgical masks in many ways," says Carlo Centonze, co-founder and CEO of HeiQ Group.\n'